I-Mab Reports Phase 1b/2 Study Results Of Patients With Advanced NSCLC Receiving Uliledlimab And Toripalimab Combination Therapy At ASCO 2023
Portfolio Pulse from Benzinga Newsdesk
I-Mab reports positive Phase 1b/2 study results for uliledlimab and toripalimab combination therapy in advanced NSCLC patients at ASCO 2023. A biomarker-guided pivotal trial is being planned.
May 25, 2023 | 9:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
I-Mab's positive Phase 1b/2 study results for uliledlimab and toripalimab combination therapy in advanced NSCLC patients may boost investor confidence.
The positive results from the Phase 1b/2 study indicate that the combination therapy of uliledlimab and toripalimab has potential in treating advanced NSCLC patients. This may lead to increased investor confidence in I-Mab's pipeline and potential future revenues, resulting in a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100